FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN), manufacturer of the first FDA-approved active patch transdermal drug delivery system, informed its shareholders of important plans to pursue an aggressive partnership and licensing strategy for its transdermal drug delivery technology, as well as restructuring of its board, management and capitalization.
